SEC Comment Letter 0000000000-25-003710 to Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc.
Date: April 7, 2025 · CIK: 0001708599 · Accession: 0000000000-25-003710
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286340
Letter
Re: Serina Therapeutics, Inc. Registration Statement on Form S-3 Filed April 2, 2025 File No. 333-286340 Dear Steven Ledger:
April 7, 2025
Steven Ledger Chief Executive Officer Serina Therapeutics, Inc. 601 Genome Way, Suite 2001 Huntsville, AL 35806
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Stephen Hinton
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 7, 2025 Steven Ledger Chief Executive Officer Serina Therapeutics, Inc. 601 Genome Way, Suite 2001 Huntsville, AL 35806 Re: Serina Therapeutics, Inc. Registration Statement on Form S-3 Filed April 2, 2025 File No. 333-286340 Dear Steven Ledger: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen Hinton </TEXT> </DOCUMENT>